Financial Performance - The company's revenue for Q3 2023 was ¥591,568,208.13, a decrease of 36.58% compared to the same period last year[5] - The net profit attributable to shareholders was -¥6,634,324.87, representing a decline of 92.88% year-on-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥42,631,405.57, down 18.55% from the previous year[5] - Total operating revenue for Q3 2023 was CNY 2,018,286,601.72, a decrease of 34.3% compared to CNY 3,067,161,380.95 in the same period last year[18] - Net profit for Q3 2023 was CNY 145,096,053.88, a decline of 26.3% compared to CNY 196,749,394.55 in Q3 2022[19] - The total comprehensive income for the third quarter was CNY 142,881,909.17, a decrease from CNY 289,534,919.49 in the previous period[20] Earnings and Shareholder Information - The company's basic and diluted earnings per share were both -¥0.0105, a decrease of 92.87% year-on-year[5] - Basic and diluted earnings per share for the quarter were CNY 0.2375, down from CNY 0.3109 year-over-year[20] - The total number of ordinary shareholders at the end of the reporting period was 45,447[11] - The top shareholder, Cui Jinhai, holds 23.02% of the shares, totaling 145,794,859 shares[11] Assets and Liabilities - Total assets at the end of the reporting period were ¥5,176,168,600.57, a decrease of 9.94% from the end of the previous year[5] - The company's total assets as of September 30, 2023, amounted to CNY 5,176,168,600.57, a decrease from CNY 5,747,507,000.10 at the beginning of the year[16] - Current assets totaled CNY 1,828,283,232.00, down from CNY 2,398,959,626.70 at the start of the year, reflecting a decline of 23.8%[15] - The total liabilities decreased to CNY 1,940,298,066.35 from CNY 2,616,522,450.63, indicating a reduction of 26.0%[16] - The company reported a total equity attributable to shareholders of ¥3,211,265,730.42, an increase of 3.55% from the previous year[5] Cash Flow - The operating cash flow net amount for the year-to-date was ¥459,259,090.89, a decrease of 49.02%[5] - Net cash flow from operating activities was CNY 459,259,090.89, significantly lower than CNY 900,860,648.94 in the same period last year[22] - Cash inflow from operating activities totaled CNY 2,379,250,640.27, compared to CNY 3,691,129,338.86 in the previous year[21] - Cash outflow from operating activities was CNY 1,919,991,549.38, down from CNY 2,790,268,689.92 year-over-year[21] - Net cash flow from investing activities was negative CNY 147,989,850.38, an improvement from negative CNY 1,067,174,157.15 in the previous year[22] - Cash flow from financing activities resulted in a net outflow of CNY 422,568,982.11, compared to a net outflow of CNY 236,928,160.88 in the same period last year[22] - The ending balance of cash and cash equivalents was CNY 393,655,682.98, an increase from CNY 280,149,583.65 year-over-year[22] - The company's cash and cash equivalents increased to CNY 522,204,672.55 from CNY 393,948,041.15, representing a growth of 32.6%[14] Operational Costs and R&D - Total operating costs for Q3 2023 were CNY 1,807,626,230.75, down 32.4% from CNY 2,675,982,938.94 year-on-year[18] - The company reported R&D expenses of CNY 60,060,955.75 for Q3 2023, an increase of 31.5% compared to CNY 45,635,755.64 in the previous year[19] Inventory and Borrowings - Inventory as of September 30, 2023, was CNY 831,236,165.09, a decrease of 5.3% from CNY 877,326,555.66 at the beginning of the year[14] - Short-term borrowings decreased significantly to CNY 443,350,309.73 from CNY 792,092,140.47, a reduction of 44.1%[16] Audit Status - The company has not undergone an audit for the third quarter report[23]

关于召开 2023 年第一次临时股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 奥美医疗用品股份有限公司（以下简称"公司"）定于2023年11月23日（星期 四）14:30召开2023年第一次临时股东大会，本次会议采取现场表决与网络投票 相结合的方式召开，现将有关事项通知如下： 证券代码：002950 证券简称：奥美医疗 公告编号：2023-025 奥美医疗用品股份有限公司 一、 召开会议的基本情况 1、会议届次：2023 年第一次临时股东大会 2、会议召集人：董事会。第三届董事会第五次会议审议通过了关于召开本 次股东大会的议案。 3、会议召开的合法、合规性：本次股东大会会议的召开符合有关法律、行政 法规、部门规章、规范性文件和《公司章程》的有关规定。 4、会议召开的日期、时间： （1）现场会议：2023 年 11 月 23 日（星期四）14:30 （2）网络投票： 通过深圳证券交易所交易系统进行网络投票的具体时间为：2023 年 11 月 23 日的交易时间，即 9:15-9:25，9:30-11:30 和 13:00-15:00； 通过深圳 ...

Financial Performance - The company's operating revenue for the first half of 2023 was approximately ¥1.43 billion, a decrease of 33.16% compared to ¥2.13 billion in the same period last year[30]. - The net profit attributable to shareholders for the first half of 2023 was approximately ¥157 million, down 45.87% from ¥290 million in the same period last year[30]. - The net cash flow from operating activities was approximately ¥207 million, a decline of 62.99% compared to ¥559 million in the same period last year[30]. - The basic earnings per share for the first half of 2023 was ¥0.248, a decrease of 45.86% from ¥0.458 in the same period last year[30]. - The total assets at the end of the reporting period were approximately ¥5.29 billion, down 7.89% from ¥5.75 billion at the end of the previous year[30]. - The net assets attributable to shareholders at the end of the reporting period were approximately ¥3.22 billion, an increase of 3.77% from ¥3.10 billion at the end of the previous year[30]. - The company reported a net profit for the first half of 2023 of CNY 154,909,401.98, a decrease of 46.5% compared to CNY 290,008,635.61 in the same period of 2022[178]. - The total comprehensive income for the first half of 2023 was CNY 152,711,366.72, compared to CNY 330,806,041.98 in the same period of 2022[178]. Market and Industry Trends - The global wound management market is expected to grow from $13 billion in 2017 to $17.8 billion by 2024, with a compound annual growth rate of 4.6%[40]. - The global bandage and medical dressing market was valued at $18.84 billion in 2015 and is projected to reach $31.3 billion by 2025[40]. - The demand for wound care is increasing due to the aging population and the rise in chronic wounds, leading to a stable growth in the medical dressing industry[40]. - The global market for medical dressings and bandages is projected to grow significantly, with a focus on high-end medical dressing products, particularly in developed economies like the EU and the US[41]. - The domestic medical dressing market in China is experiencing rapid expansion, maintaining a double-digit growth rate due to improved healthcare resources and rising living standards[43]. - China has become the largest exporter of medical dressings globally, with leading companies achieving world-class quality in traditional wound care products[43]. Product Development and Innovation - The company is focusing on the development of advanced dressing products that promote wound healing in a moist environment[39]. - The company is expanding its product line to include infection protection products and advanced dressing series, aiming to provide a comprehensive product supply service[48]. - The company’s medical dressings are designed with advanced features such as high absorption capacity and non-adhesive properties to promote healing[50]. - The company utilizes advanced materials like polyurethane films for surgical drapes, ensuring a sterile environment and preventing contamination[51]. - The company introduced advanced dressing products with unique features, including a hemostatic dressing that accelerates coagulation and absorbs liquid quickly, reducing blood loss[52]. - The hydrophilic fiber dressing can absorb liquid up to 30 times its weight, providing multifunctional benefits such as promoting healing and inhibiting bacteria[52]. - The company achieved a notable improvement in the performance of its disinfectant wipes, with a bactericidal rate of up to 99.99% against common pathogens[55]. - The company has introduced innovative products like the medical cooling patch, which provides sustained cooling for 6-8 hours[58]. Financial Management and Risks - The company faces exchange rate fluctuation risks, as a large portion of sales revenue is in foreign currencies, which can affect product pricing and operating income[8]. - The company reported a loss of 5,946.24 million CNY from derivative investments during the reporting period[86]. - The company utilized financial derivatives to hedge against exchange rate risks, effectively mitigating the impact of currency fluctuations on asset and liability values[86]. - The company has a significant market presence, exporting to nearly 40 countries and regions, with a continuous 15-year leadership in China's medical dressing export industry[65]. - The company has a competitive advantage in advanced manufacturing, quality control, and technological innovation, built over more than 20 years of development[59]. Corporate Governance and Social Responsibility - The company has actively engaged in social responsibility initiatives, including poverty alleviation and employee care programs[106]. - In 2023, the company formed five teams to visit and support employees in need, demonstrating its commitment to employee welfare[106]. - The company was recognized as a training point for employee representatives by the provincial labor union, highlighting its commitment to democratic management[107]. - The company launched a campaign to honor model workers, promoting a culture of excellence and innovation among employees[108]. Future Outlook and Strategic Plans - The future outlook includes plans for market expansion and the development of new technologies in medical supplies[53]. - The company aims to enhance its competitive edge through strategic acquisitions and partnerships in the healthcare sector[53]. - The company has established a complete industrial chain for medical dressings, infection protection products, and medical non-woven products, achieving integrated, large-scale, and intelligent production[60].

本次聘任公司高级管理人员的提名和表决程序符合《公司法》等法律法规和《公司章 程》的有关规定，合法、有效。因此，我们同意聘任黄铁柱先生为公司副总裁兼财务总监。 独立董事关于第三届董事会第四次会议相关事项的独立意见 根据《公司法》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运 作》《上市公司独立董事规则》等法律、法规、规范性文件的要求及《奥美医疗用品股份有限 公司章程》（以下简称"公司章程"）《独立董事工作制度》的相关规定，我们作为公司第三届 董事会独立董事，本着严谨、负责的态度，对提交公司第三届董事会第四次会议审议的相关 事项进行了审慎、认真的监督和审议，基于本人的独立判断，发表如下独立意见： 一、关于公司聘任副总裁兼财务总监的独立意见 经会前认真审阅黄铁柱先生的个人简历等相关资料，并了解其相关情况，未发现上述人 员存在《公司法》等法律法规、规范性文件以及《公司章程》规定的不得担任上市公司高级 管理人员的情形，也不存在被中国证监会确定为市场禁入者并且禁入尚未解除的情形，我们 认为上述人员具备有关法律法规和《公司章程》规定的任职资格，并具备相关专业知识和履 职能力。 奥美医疗用品股份有限公司 ...

证券代码：002950 证券简称：奥美医疗 公告编号：2023-019 奥美医疗用品股份有限公司 第三届董事会第四次会议决议公告 公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、误 导性陈述或重大遗漏。 一、董事会会议召开情况 奥美医疗用品股份有限公司（以下简称"公司"）第三届董事会第四次会议于 2023 年 8 月 28 日（星期一）在奥美医疗深圳会议室以现场结合通讯的方式召 开。会议通知已于 2023 年 8 月 25 日通过邮件的方式送达各位董事。本次会议 应出席董事 7 人，实际出席董事 7 人。 会议由董事长崔金海主持，监事、高管列席。会议召开符合有关法律、法规、 规章和《公司章程》的规定。经各位董事认真审议，会议形成了如下决议： 具体内容详见同日公司披露于巨潮资讯网（http://www.cninfo.com.cn）的 《关于公司财务总监辞职及聘任副总裁兼财务总监的公告》。 独立董事对本议案发表了表示同意的独立意见，具体内容详见同日公司披 露于巨潮资讯网（http://www.cninfo.com.cn）的《独立董事关于第三届董事会 第四次会议相关事项的独立意见》。 （二）审议通过 ...

2023 年半年度非经营性资金占用及其他关联资金往来情况汇总表 奥美医疗用品股份有限公司 | 单位：万元 | | --- | | | | | | | 2023 年半 | 2023 年半 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性资 | 资金占用方 | 占用方与上 | 上市公司核 | 2023 年期 | 年度占用累 | 年度占用资 | 2023 年半 | 2023 年半 | 占用形成原 | 占用性质 | | 金占用 | 名称 | 市公司的关 | 算的会计科 | 初占用资金 | 计发生金额 | 金的利息 | 年度偿还累 | 年度期末占 | 因 | | | | | 联关系 | 目 | 余额 | （不含利 | （如有） | 计发生金额 | 用资金余额 | | | | | | | | | 息） | | | | | | | 控股股东、 实际控制人 | | | | | | | | | | 非经营性占 | | 及其附属企 | | | | | | | | | | 用 | | 业 | | | | | | ...

证券代码：002950 证券简称：奥美医疗 公告编号：2023-020 奥美医疗用品股份有限公司 关于公司财务总监辞职及聘任副总裁兼财务总监的公告 经公司总裁提名，董事会提名委员会、董事会审计委员会审核，公司于2023年8月28日 召开的第三届董事会第四次会议审议通过了《关于聘任公司副总裁兼财务总监的议案》，公司 董事会聘任黄铁柱先生（简历见附件）为公司副总裁兼财务总监，任期自本次董事会审议通 过之日起至第三届董事会任期届满之日止。 独立董事就董事会聘任黄铁柱先生为财务总监发表了同意的独立意见。 特此公告。 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、 财务总监离任情况 奥美医疗用品股份有限公司（以下简称"公司"）于近日收到公司财务总监郑晓程先生的 提交的书面辞职报告。根据工作安排，郑晓程先生申请辞去公司财务总监职务，辞职后郑晓 程先生仍继续担任公司董事会秘书及其他职务。 根据《公司法》《深圳证券交易所上市公司自律监管指引第1号——主板上市公司规范运 作》及《公司章程》等有关规定，郑晓程先生的辞任自辞呈送达董事会之日起生效。截止本 公告披露日，郑晓程先 ...

证券代码：002950 证券简称：奥美医疗 公告编号：2023-018 注：合计持有股份占总股本比例尾数与各分项占比之和的尾数之差异，系四舍五入所致。 特此公告。 奥美医疗用品股份有限公司（以下简称"公司"）于近日收到了陈浩华先生发来的《关 于减持股份进展情况告知函》，其股份减持比例已超过1%。现将陈浩华先生股份减持情况公 告如下： 一、股份变动超过1%的具体情况 1.基本情况 信息披露义务人 陈浩华 住所 广东省深圳市南山区龙珠四路X号 权益变动时间 2022年12月12日-2023年8月9日 股票简称 奥美医疗 股票代码 002950 变动类型 增加□ 减少■ 一致行动人 有□ 无■ 是否为第一大股东或实际控制人 是□ 否■ 2.本次权益变动情况 股份种类（A股、B股 等） 增持/减持股数（股） 增持/减持比例（%） A股 8,231,600 1.30 合 计 8,231,600 1.30 本次权益变动方式 通过证券交易所的集中交易 ■ 通过证券交易所的大宗交易 □ 3. 本次变动前后，投资者及其一致行动人拥有上市公司权益的股份情况 股份性质 本次变动前持有股份 本次变动后持有股份 股数(股) 占总股本比 ...

证券代码：002950 证券简称：奥美医疗 公告编号：2023-019 奥美医疗用品股份有限公司 关于持股5%以上股东减持计划时间过半的进展公告 陈浩华先生保证向本公司提供的信息内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 奥美医疗用品股份有限公司（以下简称"公司"）于近日收到陈浩华先生的《关于减持股份 进展情况告知函》，截至本公告披露日，较公司在巨潮资讯（http://www.cninfo.com.cn）及《中 国证券报》《上海证券报》《证券时报》《证券日报》披露的《关于于持股5%以上的股东股份减 持计划提前终止暨后续减持计划的预披露公告》（公告编号：2023-014）减持数量已过半。依 据《上市公司股东、董监高减持股份的若干规定》（证监会公告 [2017] 9号）及《深圳证券交 易所上市公司股东及董事、监事、高级管理人员减持股份实施细则》的有关规定，现将陈浩 华先生预披露的减持计划实施进展情况公告如下： 一、 股东减持情况 | 股东名称 | 减持方式 | 减持期间 | | 减持均价 | 减持股数（股） | 减持 ...

股票代码：002950 证券简称：奥美医疗 编号：2023 - 002 投资者关系活动类别 ☐特定对象调研 ☐分析师会议 ☐媒体采访 业绩说明会 ☐新闻发布会 ☐路演活动 ☐现场参观 ☐其他（请文字说明其他活动内容） 线上参与2023年湖北辖区上市公司投资者网上集体接待 参与单位名称及人员 日的全体投资者 姓名 时间 2023年5月25日 14:30-16:35 地点 全景网（https://rs.p5w.net/html/138741.shtml） 上市公司接待人员姓名 董事会秘书、财务总监 郑晓程 证券事务代表 王远东 1. 公司今年的战略目标是什么？ 答：尊敬的投资者您好！公司在2022年年报中将产品 投资者关系活动主要 类别基于战略规划进行了重新分类，以下四类产品均是公 司的发力重点。①外科与伤口护理类主要系公司传统医用 内容介绍 敷料产品，目前公司正在着力扩大该产品在海外市场的市 占率，自2008年至今，公司已连续15年占据中国医用敷 料出口行业第一的位置。②感染防护类系公司基于院内感 染防护、手术室感控、医技操作感控等场景推出的产品， 该类产品在海外有较大的市场容量；同时，随着国内对院 感的重视， ...